ArticleCancer gene therapy2011
Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.
Article in Cancer gene therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Engineering HSV-1 for oncolytic therapy: From molecular entry mechanisms to retargeting strategies.Genes & diseases · 2026Review
- Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy.Nature cancer · 2026Article
- Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus.Journal of Cancer · 2026Review
- Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis.Cancers · 2022Article
- Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.Oncology letters · 2021Article
- Oncolytic Virotherapy: From Bench to Bedside.Frontiers in cell and developmental biology · 2021Review
- Review
- Advances in the mechanisms of action of cancer-targeting oncolytic viruses.Oncology letters · 2018Article
- Review
- A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4.Oncotarget · 2015Article
- Glioma virus therapies between bench and bedside.Neuro-oncology · 2014Review
- The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.British journal of cancer · 2014Article
- Gene therapy for malignant glioma.Molecular and cellular therapies · 2014Review
- The art of gene therapy for glioma: a review of the challenging road to the bedside.Journal of neurology, neurosurgery, and psychiatry · 2013Review
- Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.Translational oncology · 2012Article
- The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Recent advances in oncolytic virus design.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011Review
- Article
- Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Molecular therapy oncolyticsArticle
- Designing Herpes Viruses as Oncolytics.Molecular therapy oncolyticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We exploited the differential activation of hypoxia-inducible factor (HIF)-dependent gene expression in tumors versus normal tissue for the design of a targeted oncolytic herpes simplex virus type-1 (HSV-1). A gene that is essential for viral replication, infected cell polypeptide 4 (ICP4), was placed under the regulation of an HIF-responsive promoter and then introduced into the thymidine kinase locus (U(L)23) of HSV d120, which contains partial deletions in the two endogenous ICP4 genes. Recombinant HIF-HSV was isolated and their derivation from d120 was verified by expression of a truncated, non-functional form of ICP4 protein. Disruption of the U(L)23 locus was confirmed by loss of thymidine kinase expression and resistance to acyclovir. Unexpectedly, HIF-HSV expressed ICP4 and induced tumor cell lysis at similar levels under normoxia and hypoxia. The lack of HIF-dependent ICP4 transgene expression by HIF-HSV was due to two factors that have not previously been reported-reversion of the ICP4 gene region to its wild-type configuration and increased HIF-transcriptional activity under normoxia when cells were infected with any strain of HSV-1. The findings that an oncolytic HSV-1 is genetically unstable and can activate a tumor-related promoter in a non-specific manner have important implications for any proposed use of this virus in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.